Europe is risking ‘health sovereignty’ by underpaying for drugs, says AstraZeneca
CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere
Related reading
Britain is squeezing AstraZeneca too tight
NHS curbs on drug prices have alienated UK pharma companies and become self-defeating
Europe’s pharma industry risks lagging behind US and China, says German…
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
US drugmakers threaten to withhold products from Europe over prices
Pharmaceutical companies seek to make up any lost revenue after striking deals with Donald Trump to lower costs in US
EU to stockpile key drugs to avoid repeat of pandemic-era panic buying
Member states agree on Critical Medicines Act that aims to incentivise domestic production
European businesses warn Brussels over push to end reliance on US tech
Companies argue that ‘tech sovereignty’ drive could hit profits and undermine continent’s competitiveness
AstraZeneca bounces back from scandal in China
Pharma group has installed new leadership in the country and pledged $2.5bn for a Beijing R&D centre